INFORMATION:
Antiarrhythmia drugs no impact on late AF recurrence
2015-08-30
(Press-News.org) LONDON, UK - In patients with atrial fibrillation (AF) treated with radiofrequency catheter ablation, the addition of antiarrhythmic drugs (AADs) for 90 days after the procedure did not reduce arrhythmia recurrence rates at one year, according to results of the Efficacy of Antiarrhythmic Drugs Short-Term Use after Catheter Ablation for Atrial Fibrillation (EAST-AF) trial.
Results of the study, presented as a Hot Line at ESC Congress 2015
The study did show a temporary benefit of AAD, but the effect disappeared as soon as medication was stopped, suggesting no benefit to making post-ablation AAD therapy standard practice, said study investigator Kazuaki Kaitani, MD, from Tenri Hospital in Tenri, Nara, Japan.
Radiofrequency ablation around the pulmonary veins, known as "pulmonary vein isolation" (PVI), is the standard treatment for AF, but recurrence is common.
Short-term (6 weeks) therapy with AADs after PVI for paroxysmal AF has been previously shown to reduce early arrhythmia recurrence rates compared to no AADs, but this benefit disappeared after treatment discontinuation
The EAST-AF trial investigated whether a longer treatment period might extend the benefit beyond AAD discontinuation.
The study included 2,044 patients (mean age 63 years) undergoing first radiofrequency catheter ablation for AF at 19 cardiovascular centres in Japan.
Patients were randomised to treatment with AADs (n=1,016) or a control group (n=1,022) for 90 days after the procedure.
The primary endpoint of the study was arrhythmias lasting for more than 30 seconds or requiring repeat ablation, hospital admission, cardioversion or AADs between 3 months and 1-year post ablation.
While there was a significantly lower rate of early arrhythmia recurrences in the AAD group compared with the control group during the treatment period (41.0% versus 47.9%, respectively; P=0.013), this benefit did not persist after AAD discontinuation.
The 1-year recurrence-free rate was 69.5% in the AAD group and 67.8% in the control group, with no significant difference between the two groups (adjusted hazard-ratio [HR] 0.93; 95% confidence-interval, 0.79 to 1.09; P=0.38).
In addition, this finding was consistent across all prespecified subgroups, including patients with paroxysmal AF versus those with persistent or long-lasting AF.
"Therefore, we concluded that the short-term use of AADs for 90-days following catheter ablation of AF reduces the incidence of recurrent AF during the 90-day treatment period, but does not lead to improved clinical outcomes in the later phase," he said.
ELSE PRESS RELEASES FROM THIS DATE:
Multiple risk factors cancel impact of atrial fibrillation on ischemic stroke risk
2015-08-30
London, UK - 30 Aug 2015: The impact of atrial fibrillation on ischaemic stroke risk in elderly patients is eliminated with multiple risk factors, according to an 11 year study in more than 425 000 patients presented at ESC Congress today.1 The findings suggest that stroke prevention in the elderly may need to focus on the concomitant effects of multiple risk factors rather than on a specific risk factor such as atrial fibrillation (AF).
"The incidence of ischaemic stroke increases with greater numbers of cardiovascular risk factors," said principal investigator Dr Yutao ...
Rapid, more sensitive test speeds up chest pain triage
2015-08-30
LONDON, England - 30 August, 2015: Patients arriving at the emergency department with chest pain suggestive of acute myocardial infarction (AMI) can be triaged more quickly and more safely using a new rapid assay with refined cut-offs, German research suggests.
The Biomarkers in Acute Cardiovascular Care (BACC) study, presented as a Hot Line at ESC Congress 2015, suggests this new algorithm can reduce mortality and cut triage times to one hour, compared to the standard three-hour approach.
"There is an urgent need for fast decision-making for this growing patient population," ...
Antimineralocorticoids offer no benefit in heart attack patients without heart failure
2015-08-30
LONDON, UK - 30 August, 2015: Heart attack patients without heart failure derive no benefit from the addition of mineralocortoid receptor antagonists (MRA), to standard therapy, results of the ALBATROSS study show.
The Hot Line findings, reported at ESC Congress 2015, "do not warrant the extension of MRA use" to such patients, said the study's principal investigator Gilles Montalescot, MD, PhD.
MRAs, also known as aldosterone antagonists, inhibit sodium retention and excretion of potassium and magnesium, and therefore "there is an indication for MRA therapy in MI ...
Peri-infarct pacing does not improve outcomes in patients with large myocardial infarction
2015-08-30
LONDON, UK - In patients with a large myocardical infarction (MI), pacing, with the left ventricular (LV) lead placed in the area of the lesion (peri-infarct) did not prevent further enlargement of the heart (remodeling), nor did it improve functional or clinical outcomes after 18 months, according to results of the Pacing Remodeling Prevention Therapy trial (PRomPT) trial.
In MI patients with large infarcts, medical therapy and rapid restoration of blood flow to the area is not always enough to prevent cardiac remodeling.
One reason for remodeling may be the response ...
Cyclosporine does not improve outcomes after PCI
2015-08-30
LONDON, UK - 30 August, 2015: The immunosuppressant drug cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention (PCI) for the more severe form of heart attack known as ST-segment elevation myocardial infarction (STEMI).
Results of the CIRCUS trial, presented today in a Hot Line session at ESC Congress 2015, and published simultaneously in the New England Journal of Medicine. showed that the drug, administered prior to PCI, had no impact on a composite of all-cause death, hospitalisation for - or worsening ...
Surprise cardiac finding predicts future risk
2015-08-30
LONDON, UK - In patients with chronic ischemic heart disease, a small left ventricle with thick walls, is the strongest predictor of morphologic remodelling, which is generally considered a first step towards heart failure, according to unexpected findings presented today at ESC Congress 2015.
Results of the DOPPLER-CIP (which stands for "Determining Optimal non-invasive Parameters for the Prediction of Left vEntricular morphologic and functional Remodeling in Chronic Ischemic Patients") study were not expected and, if confirmed by other studies, "could completely change ...
How can we prevent suicide? Major study shows risk factors associated with depression
2015-08-30
A major multi-national study of suicides has identified the behaviour patterns which precede many suicide attempts. This may lead to changes in clinical practice in the care of patients affected with depression, as it shows the clinical factors which confer major risk of suicide attempts.
The statistics for suicide are frightening. According to the WHO, more than 800,000 people commit suicide every year, with perhaps 20 times that number attempting suicide. Suicide is one of the leading causes of death in the young (in the UK for example, it is the leading cause of death ...
Scientists show how magnetic pulses change the brain in treatment for depressed patients
2015-08-30
A group of UK scientists have found a way of understanding how transcranial magnetic stimulation (TMS) can give relief to severely depressed patients. TMS is used as an alternative to Electro-Convulsive Therapy (ECT)*, but it is not known how it achieves its therapeutic effect. Understanding how it works may open the door to better, more targeted treatment for depression and other conditions.
Transcranial magnetic stimulation works by applying a magnetic pulse to the frontal part of the brain of depressed patients. Like ECT, it seems to 'reset' the brain, but is easier ...
A single cocaine dose lowers perceptions of sadness and anger
2015-08-30
A single dose of cocaine can interfere with the ability to recognise negative emotions, according to new research presented at the ECNP conference in Amsterdam.
In a placebo-controlled within subject study, researchers from the Netherlands and Germany took 24 students (aged 19 to 27) with light to moderate cocaine use, and gave them either 300mg of oral cocaine, or a placebo.
After 1 to 2 hours, each participant was then subject to a series of biochemical tests, as well as the facial emotion recognition test to measure response to a series of basic emotions, such ...
Depression and extremes of blood pressure predict highest rates of harmful vascular events
2015-08-29
London, UK - 29 Aug 2015: Depressive symptoms and extremes of blood pressure predict the highest rates of harmful vascular events in patients with existing heart disease, diabetes or stroke, according to research presented at ESC Congress today by Dr Bhautesh Jani, clinical academic fellow in the Institute of Health and Wellbeing, University of Glasgow, UK.1
The study in more than 35 000 patients found that the risk of further stroke or heart attack, heart failure or dying due to heart disease at four years was 83% higher in depressed patients with high blood pressure ...